Keringő mikroRNS-ek az endokrin daganatok                     diagnosztikájában

Decmann, Ábel; Perge, Pál; Nagy, Zoltán; Butz, Henriett; Patócs, Attila; Igaz, Péter

doi:10.1556/650.2017.30708

Cited by 8 publications

(4 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The prognosis is further worsened by the difficulty of diagnosing and the limited therapeutic options. Compared with adrenal adenoma, under-expression of miR-195 and overexpression of miR-34a and miR-483–5p were found in ACC, and the prognostic significance of miR-483-5p was also suggested [56]. The overexpression of miR-100, miR-181b, miR-184, miR-210, and miR-483-5p was also significant in ACC compared to adrenocortical adenoma [57].…”

Section: Adrenocortical Carcinomamentioning

confidence: 91%

Molecular tools for diagnosing diseases of the adrenal cortex

Faucz

Maria²,

Stratakis

2023

Current Opinion in Endocrinology, Diabetes &Amp; Obesity

View full text Add to dashboard Cite

Purpose of reviewThe adrenal glands produce some of the most essential for life hormones, including cortisol and other steroids, and catecholamines. The former is produced from the adrenal cortex, whereas the latter is from the medulla. The two parts are anatomically and functionally distinct and it would be impossible in the context of one short article to cover all molecular updates on both the cortex and the medulla. Thus, in this review, we focus on the molecular tools available for diagnosing adrenocortical diseases, such as adrenal insufficiency, Cushing and Conn syndromes, and their potential for advancing medical care and clinical outcome. Recent findingsThe advent of next generation sequencing opened doors for finding genetic diseases and signaling pathways involved in adrenocortical diseases. In addition, the combination of molecular data and clinicopathologic assessment might be the best approach for an early and precise diagnosis contributing to therapeutic decisions and improvement of patient outcomes.

show abstract

Section: Adrenocortical Carcinomamentioning

confidence: 91%

Molecular tools for diagnosing diseases of the adrenal cortex

Faucz

Maria²,

Stratakis

2023

Current Opinion in Endocrinology, Diabetes &Amp; Obesity

View full text Add to dashboard Cite

show abstract

“…A vérben lévő miRNS vizsgálata ugyanakkor megfelelő eszközként szolgálhat [47,48]. A mellékvesekéregcarcinoma azonosítására, úgy tűnik, hogy a keringő MiR-483-5p miRNS mennyiségének vizsgálata lehet az egyik legérzékenyebb módszer [49].…”

Section: Noninvazív Biomarkerek a Mellékvese-carcinomák Diagnózisában...unclassified

A mellékvesekéreg-carcinoma diagnosztikája

Tőke,

Tóth

2024

View full text Add to dashboard Cite

A mellékvesekéreg-carcinoma ritka, rossz prognózisú megbetegedés. Az érintett betegek kórjóslatát döntően meghatározza, hogy a betegség korán, még lokoregionális stádiumban kerüljön felismerésre, amikor a sebészi tumoreltávolítással jelentősen növelhető a gyógyulás esélye. A mellékvese-daganatok dignitásának meghatározása gyakran jelent kihívást a preoperatív kivizsgálás során, a diagnózisalkotást hagyományos radiológiai és laboratóriumi vizsgálatok segítik. Újabban igen jó diagnosztikai pontosságot mutató biomarkerek is megismerésre kerültek, klinikai használatuk a közeljövőben várható. Közülük is kiemelkednek a gáz-, illetve folyadékkromatográfián alapuló szteroidmetabolomikai vizsgálatok, valamint a miRNS-ek vizsgálata. Ebben az összefoglalóban bemutatjuk a mellékvesekéreg-carcinoma azonosítását segítő preoperatív klinikai és posztoperatív patológiai vizsgálómódszereket. Orv Hetil. 2024; 165(4): 123–131.

show abstract

“…MicroRNA (miRNA) is a short single stranded non-coding RNA molecule involved in the epigenetic regulation of cellular processes [173][174][175]. MicroRNAs regulate gene expression by inhibiting mRNA translation or degrading mRNA transcripts [176].…”

Section: Micrornamentioning

confidence: 99%

The Role of Biomarkers in Adrenocortical Carcinoma: A Review of Current Evidence and Future Perspectives

2021

View full text Add to dashboard Cite

Adrenocortical carcinoma (ACC) is a rare endocrine malignancy arising from the adrenal cortex often with unexpected biological behavior. It can occur at any age, with two peaks of incidence: in the first and between fifth and seventh decades of life. Although ACC are mostly hormonally active, precursors and metabolites, rather than end products of steroidogenesis are produced by dedifferentiated and immature malignant cells. Distinguishing the etiology of adrenal mass, between benign adenomas, which are quite frequent in general population, and malignant carcinomas with dismal prognosis is often unfeasible. Even after pathohistological analysis, diagnosis of adrenocortical carcinomas is not always straightforward and represents a great challenge for experienced and multidisciplinary expert teams. No single imaging method, hormonal work-up or immunohistochemical labelling can definitively prove the diagnosis of ACC. Over several decades’ great efforts have been made in finding novel reliable and available diagnostic and prognostic factors including steroid metabolome profiling or target gene identification. Despite these achievements, the 5-year mortality rate still accounts for approximately 75% to 90%, ACC is frequently diagnosed in advanced stages and therapeutic options are unfortunately limited. Therefore, imperative is to identify new biological markers that can predict patient prognosis and provide new therapeutic options.

show abstract

Keringő mikroRNS-ek az endokrin daganatok diagnosztikájában

Cited by 8 publications

References 49 publications

Molecular tools for diagnosing diseases of the adrenal cortex

Molecular tools for diagnosing diseases of the adrenal cortex

A mellékvesekéreg-carcinoma diagnosztikája

The Role of Biomarkers in Adrenocortical Carcinoma: A Review of Current Evidence and Future Perspectives

Contact Info

Product

Resources

About